Portal de Periódicos da CAPES

Modulation of Rapid Plasminogen Activator Inhibitor in Plasma by Stanozolol

1984; Thieme Medical Publishers (Germany); Volume: 51; Issue: 03 Linguagem: Inglês

10.1055/s-0038-1661110

2567-689X

Jan H. Verheijen, D C Rijken, G T G Chang, F E Preston, C Kluft,

Blood Coagulation and Thrombosis Mechanisms

Summary Fibrinolytic activity in plasma euglobulin fractions can be increased by oral administration of stanozolol. This increase is not caused by increased synthesis or release of tissue-type plasminogen activator. A decreased level of fast acting t-PA inhibition is very probably the cause of the higher activity. These results suggest that this inhibition has a regulatory role on fibrinolysis in vivo.